Arno Therapeutics, Inc. HomeAbout UsPipelineInvestor RelationsContact Us
Arno Therapeutics is a biopharmaceutical company focused on the clinical development of targeted cancer therapies and novel drug candidates for unmet medical needs
Arno Theraoeutics, Inc.
Recent Press Releases In the news Contact

April 21, 2015
Arno Therapeutics to Present Promising Data from Phase I Trial of Onapristone at AACR Annual Meeting 2015 more »

April 13, 2015
Arno Therapeutics Announces Three Poster Presentations at Upcoming AACR Annual Meeting 2015 more »

March 31, 2015
Arno Therapeutics Reports Fourth Quarter 2014 Financial and Business Update more »

March 24, 2015
New Data Supporting Arno Therapeutics' HDAC inhibitor AR-42 Published in The Journal of Urology more »

January 8, 2015
Arno Therapeutics to Present at 11th Annual Noble Equity Conference more »

View all Press Releases


April 8, 2015
Arno Therapeutics Seeks to Inhibit Cancer and Enhance Portfolios: CEO Alexander Zukiwski more »

May 23, 2014
Express Yourself: Arno, University of Minnesota pursue gene expression in hopes of developing a companion diagnostic more »

May 19, 2014
Do the Math: Ram Selvaraju on the Appeal of Biotechs in Orphan Diseases more »

May 9, 2014
Maxim: ARNI - Clinical progress on track; Onapristone in two dose escalation trials; Reiterating Buy and $6 price target more »

January 22, 2014
Maxim: ARNI - Onapristone now in clinical development; Revising estimates; Reiterating Buy and $6 price target more »

July 15, 2013
Orphan-Drug Marketing - Medical Marketing & Media (MM&M) eBook more »

July 8, 2013
APRs in CTCs - Drug Discovery News more »

June 13, 2013
Arno Therapeutics’ strategy is to develop onapristone companion diagnostics for each indication - Biopharm Insight more »

View All News


Arno Therapeutics, Inc.
200 Route 31 North
Suite 104
Flemington, NJ 08822

(862) 703-7170 Main
(908) 237-0071 Fax
info@arnothera.com